MD3244F1 - Method of determining the endometrial cancer aggressivity - Google Patents

Method of determining the endometrial cancer aggressivity

Info

Publication number
MD3244F1
MD3244F1 MDA20060139A MD20060139A MD3244F1 MD 3244 F1 MD3244 F1 MD 3244F1 MD A20060139 A MDA20060139 A MD A20060139A MD 20060139 A MD20060139 A MD 20060139A MD 3244 F1 MD3244 F1 MD 3244F1
Authority
MD
Moldova
Prior art keywords
endometrial cancer
determining
units
level
determined
Prior art date
Application number
MDA20060139A
Other languages
Romanian (ro)
Other versions
MD3244G2 (en
Inventor
Dumitru Sofroni
Lilian GUTU
Katja Tenner
Anatolie CERNII
Corina Cardaniuc
Mihail Todiras
Michael Bader
Original Assignee
Institutia Medico-Sanitara Publica Institutul Oncologic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institutia Medico-Sanitara Publica Institutul Oncologic filed Critical Institutia Medico-Sanitara Publica Institutul Oncologic
Priority to MDA20060139A priority Critical patent/MD3244G2/en
Publication of MD3244F1 publication Critical patent/MD3244F1/en
Publication of MD3244G2 publication Critical patent/MD3244G2/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Inventia se refera la medicina, in special la oncologie si poate fi utilizata pentru aprecierea precoce neinvaziva a agresivitatii cancerului endometrial. Esenta inventiei consta in aceea ca se determina in tesuturile endometrial si miometrial nivelul de ARN mesager pentru triptofanhidroxilaza-1,si in cazul, in care nivelul constituie 0…15 unitati se determina o agresivitate majora, 16…400 unitati – o agresivitate medie, 400 unitati si mai mult se determina o agresivitate scazuta a cancerului endometrial.The invention relates to medicine, especially oncology and can be used for early noninvasive assessment of endometrial cancer aggressiveness. The essence of the invention is that the level of messenger RNA for tryptophanhydroxylase-1 is determined in the endometrial and myometrial tissues, and if the level is 0… 15 units, major aggression is determined, 16… 400 units - average aggressiveness, 400 units and more causes low aggression of endometrial cancer.

MDA20060139A 2006-05-15 2006-05-15 Method of determining the endometrial cancer aggressivity MD3244G2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDA20060139A MD3244G2 (en) 2006-05-15 2006-05-15 Method of determining the endometrial cancer aggressivity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDA20060139A MD3244G2 (en) 2006-05-15 2006-05-15 Method of determining the endometrial cancer aggressivity

Publications (2)

Publication Number Publication Date
MD3244F1 true MD3244F1 (en) 2007-02-28
MD3244G2 MD3244G2 (en) 2007-12-31

Family

ID=37845198

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20060139A MD3244G2 (en) 2006-05-15 2006-05-15 Method of determining the endometrial cancer aggressivity

Country Status (1)

Country Link
MD (1) MD3244G2 (en)

Also Published As

Publication number Publication date
MD3244G2 (en) 2007-12-31

Similar Documents

Publication Publication Date Title
CY1117784T1 (en) METHODS AND RECOMMENDATIONS FOR DIAGNOSIS AND PREDICTION OF DYNAMIC DAMAGE AND DYNAMIC DEFICIENCY
EA200801046A1 (en) NON-INVASIVE METHOD FOR IDENTIFYING TRANSITIONAL CELL CARCINOMA OF URINARY BUBBLE IN VITRO
EP3311818A3 (en) Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
EP1904290A4 (en) Aluminum phosphate based microspheres
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
EA200870029A1 (en) METHOD OF APPLICATION OF IL-6 ANTAGONISTS WITH PROTEAS INHIBITORS
CR20160355A (en) NEUTRALIZING ANTIBODIES OF HUMAN ATOMEGALOVIRUS AND USE OF THE SAME
MA31435B1 (en) Malignant metastases inhibitor by antibody anti-norobillin 2.
UY27729A1 (en) QUINASE INHIBITORS.
WO2007051065A3 (en) Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
MX2010006854A (en) Biomarkers for sensitivity to anti-igf1r therapy.
ATE420883T1 (en) PYRROLOPYRIMIDINES USED AS PROTEIN KINASE INHIBITORS
CY1113984T1 (en) DM1 conjugate conjugate products with TRASTUZUMAB antibody, CONNECTED THROUGH NON-EXTRACTIVE CONNECTOR AND USE IN TREATMENT TREATMENT
DE60332433D1 (en) AZOLYLAMINOAZINE AS PROTEIN KINASE INHIBITOR
DE60332604D1 (en) AZOLYLAMINOAZINE AS PROTEIN KINASE INHIBITOR
ATE451376T1 (en) COMPOSITIONS SUITABLE AS INHIBITORS OF PROTEIN KINASES
DE602004024374D1 (en) COMPOSITIONS FOR USE AS PROTEIN KINASE INHIBITORS
BRPI0518228B8 (en) mitotic kinesin inhibitors and their use
MA33323B1 (en) ADJUVANT THERAPY OF CANCER
BRPI0707040B8 (en) In vitro method of selecting a compound, in vitro method of predicting the presence of cancer, method of in vitro determination of the efficiency of an anticancer treatment and use of a compound
BRPI0412217A (en) antibody efficacy evaluation method, immunotherapy methods, therapeutic antibody neutralizing antibody detection method and antagonist efficacy evaluation method
EA200400029A1 (en) ANTAGONIST COMBINATION OF ALCHOSTERONE RECEPTOR AND HMG-COA REDUCTASE INHIBITOR
ATE555656T1 (en) USE OF VISION INHIBITORS AS ANALGESICS
MX2010008496A (en) Method for determination of sensitivity to anti-cancer agent.
WO2006116016A3 (en) Molecular determinants of egfr kinase inhibitor response in glioblastoma

Legal Events

Date Code Title Description
FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees